H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Enlivex today and set a price target of $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors including the recent issuance of an Israeli patent for Enlivex’s Allocetra, which provides intellectual property protection until 2040 for its use in treating osteoarthritis. This patent strengthens Enlivex’s position in the market and supports the company’s ongoing clinical developments. Additionally, the positive results from the Phase 2a clinical trial for knee osteoarthritis have been well-received by key opinion leaders, further validating the potential of Allocetra.
Enlivex’s strategic roadmap, as outlined by CEO Oren Hershkovitz, includes advancing Allocetra into Phase 2b testing and pursuing partnerships with larger companies interested in osteoarthritis. The company’s efforts to explore Allocetra’s applicability in other osteoarthritis sub-indications, such as basal thumb OA and TMJ OA, also contribute to the Buy rating. These developments, along with the anticipated release of additional data sets, position Enlivex for potential growth and make it an attractive investment opportunity.